In June 2026, Reed Semiconductor closed a $100 million funding round backed by several leading global semiconductor companies. The round was oversubscribed. Investors wanted in faster than Reed could allocate. The company builds power management chips for AI data centers from its headquarters in Warwick, Rhode Island. This is the
$75 million. Oversubscribed. For a platform most biotech investors haven't heard of — yet. Lycia Therapeutics, a South San Francisco biotech built on Nobel Prize-winning chemistry, closed its Series D on June 25. The round was co-led by Janus Henderson and Balyasny Asset Management, with participation from
A&K Robotics raises $8M Series A to scale Cruz autonomous pods at Vancouver and Madrid airports. The company's crowd-aware Kinesos AI tackles indoor mobility where road AVs don't go.
Omni Analytics raised $120M Series C at $1.5B valuation. The ex-Looker team's semantic layer bet: making enterprise AI data trustworthy.
London biotech RQ Bio raised $115M for RQB01, a long-acting antibody aiming to replace annual flu shots for high-risk patients.
Baseten tripled ARR to $600M in one quarter, raised $1.5B at $13B. The inference infrastructure market has arrived.
IN-SPACe selects Astrobase, SatSure and TM2SPACE as first beneficiaries of ₹500 crore Technology Adoption Fund — covering propulsion, Earth observation AI, and satellite navigation
Robotics venture funding hit $23B in the first half of 2026, matching all of 2025. Here is where the money is going — by company, category, and geography.